|Drug class||Mast cell stabilizer|
|Main uses||Allergic conjunctivitis|
|Side effects||Eye discomfort, dry eyes|
|Typical dose||1 to 2 drops QID|
|Chemical and physical data|
|Molar mass||311.63 g·mol−1|
Lodoxamide, sold under the brand name Alomide among others, is a medication used to treat allergic conjunctivitis. It is used as an eye drop. It may be used in children over the age of 2 years.
Lodoxamide was approved for medical use in the United States in 1993. In the United Kingdom a 10 ml bottle costs the NHS about £5 as of 2021. In the United States this amount costs about 175 USD.
In 2014 lodoxamide and bufrolin were found to be potent agonists at the G protein-coupled receptor 35, an orphan receptor believed to play a role in inflammatory processes, pain and the development of stomach cancer.
- "Lodoxamide Monograph for Professionals". Drugs.com. Retrieved 24 November 2021.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1206. ISBN 978-0857114105.
- "Lodoxamide ophthalmic (Alomide) Use During Pregnancy". Drugs.com. Retrieved 24 November 2021.
- "Lodoxamide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 24 November 2021.
- MacKenzie, AE; Caltabiano, G; Kent, TC; Jenkins, L; McCallum, JE; Hudson, BD; Nicklin, SA; Fawcett, L; Markwick, R; Charlton, SJ; Milligan, G (2014). "The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35". Molecular Pharmacology. 85 (1): 91–104. doi:10.1124/mol.113.089482. ISSN 0026-895X. PMC 3868900. PMID 24113750.